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panded CD425 cells prevent BM graft rejection in sublethally
irradiated recipients via a TGF	-independent mechanism. Hanash
and Levy have shown that the addition of donor CD425 cells
resulted in greater lineage committed and multi-potential donor
progenitors in recipient spleens one week post-transplant and sig-
niﬁcantly increased long-term multi-lineage donor chimerism in
sublethally irradiated recipients. A major limitation for the clinical
application of human CD4CD25 cells has been their paucity in
peripheral blood. Only the CD425bright cells are potent sup-
pressors and such cells typically are hypoproliferative. Although
exogenous IL-2 can support human CD4CD25 cell prolifera-
tion the initial protocols published for human CD4CD25 T
cells resulted in limited expansion. However, recent publications
have solved this problem. Studies by Godfrey et al have used a
non-cell sorter, bead-based approach to isolate CD425hi cells
from adult peripheral blood mononuclear cells that were able to be
expanded 100-fold in 2-3 weeks. These expanded CD425
cells were far more potent suppressors of MLR cultures than fresh
cells and retained the expression of L-selhi and other LN homing
receptors. Hoffmann et al have shown that CD425bright cells
can be isolated using cell sorting approaches and that such isolated
cells can be expanded in great numbers while still retaining expres-
sion of L-selhi. Recent studies by Godfrey et al have shown that
cord blood cell CD425 cells are more readily isolated and more
often lead to high levels of suppression as compared to adult
peripheral blood mononuclear cells. These preliminary ﬁndings
demonstrating a high degree of MLR suppression now have been
extended in subsequent studies using 100 cord blood lines gen-
erated to date (B. Blazar and S. Porter, unpublished data). Thus,
the stage is set for clinical trials of CD425 cells for GVHD
inhibition and therapy and engraftment promotion.
12
TRANSPLANTATION OF EX VIVO EXPANDED CORD BLOOD
Shpall, E.J.1, de Lima, M.1, McMannis, J.D.1, Robinson, S.1, McNiece,
I.K.2, Champlin, R.E.1 1. The M.D. Anderson Bone Marrow Trans-
plant Department, Houston, TX; 2. Johns Hopkins Oncology Center,
Baltimore, MD
Umbilical cord blood (CB) from unrelated donors is increasingly
used to restore hematopoiesis after myeloablative or more recently,
nonmyeloablative therapy. CB transplants are associated with
higher rates of delayed and failed engraftment than are bone
marrow transplants, particularly for adult patients. At the Univer-
sity of Colorado, we studied the ex vivo expansion of CB in an
attempt to improve time to engraftment and reduce the graft
failure rate in the recipients. In the study, 43 patients with hema-
tologic malignancies (n  40) or breast cancer (n  3) received
high-dose therapy followed by unrelated allogeneic CB transplan-
tation. A fraction of each patient’s CB allograft was CD34-selected
and cultured ex vivo for 10 or 14 days prior to transplantation in
deﬁned media with stem cell factor (SCF), granulocyte colony-
stimulating factor (G-CSF), and megakaryocyte growth and dif-
ferentiation factor (MGDF). The remainder of the CB graft was
infused without further manipulation. Two sequential cohorts of
patients were accrued to the study. The ﬁrst cohort had 40% and
the second cohort had 60% of their CB graft expanded. This study
demonstrated that the CD34 selection and ex vivo expansion of CB
prior to transplantation is feasible. The engraftment failure rate
was relatively low, and the time to neutrophil engraftment in large
adults was in the range reported for pediatric recipients of much
larger CB cell doses. In the successor cord expansion trial being
conducted at the MD Anderson Cancer Center, several changes in
the approach have been made. Patients with hematologic malig-
nancies are now being randomized to receive either two unma-
nipulated CB units or one unmanipulated unit and one unit from
which all the cells are expanded ex vivo. For the patients random-
ized to expansion, on day 
14 one of their cord units is CD133-
selected using the CliniMACS device. The CD133-negative frac-
tion containing the T cells is frozen and the CD133 fraction is
cultured ex vivo for 14 days in media containing SCF, G-CSF and
thrombopoietin (TPO). Following administration of the prepara-
tive regimen, on Day 0, the second unmanipulated CB unit is
infused, followed by the thawed CD133-negative fraction and
ﬁnally, the fraction which has been in culture for two weeks. This
trial was recently initiated and accrual is in progress. Another
expansion trial technology involves the use of a copper chelating
agent, which has been shown by Peled et al to enhance the expan-
sion of a more primitive CD34 CB population when combined
with early acting growth factors. A clinical trial employing this
technology is in progress at MD Anderson. Patients with hemato-
logic malignancies undergoing CB transplantation, with a unit that
is cryopreserved in two fractions are eligible for the study. Twenty
one days prior to infusion, the CD133 cells are isolated from the
smaller cord fraction using the CliniMACS device and cultured for
three weeks in media containing interleukin-6 TPO, FLT-3, SCF,
and the copper chelator tetraethylenepentamine (TEPA). The pa-
tients then receive high-dose therapy with the infusion of the
larger, unmanipulated CB fraction on day 0, and infusion of the
smaller expanded fraction of day 1. Thus far 10 patients have
been enrolled on the study. Evaluable patients engrafted neutro-
phils a median of 27 (range 16-46) in and platelets in a median of
52 (range 27-105) days. An alternative approach for ex vivo expan-
sion is the co-culture of CB cells with bone marrow mesenchymal
stem cells (MSCs) which provide a microenvironment for the
complex molecular cues that direct self-renewal/proliferation and
regulate the differentiation and maturation of hematopoietic prog-
eny. McNiece et al have reported impressive expansion of CB on
MSC stroma. Robinson et al have shown superior expansion of CB
in MSC co-cultures when compared to liquid cultures of the same
CD133 CB fractions. Infusion of MSCs has been shown to
promote engraftment of human CD34 cells in NOD/SCID mice
and fetal sheep. Importantly MSC have been shown to have im-
munomodulatory activity which may reduce graft versus host dis-
ease and enhance engraftment in patients. Clinical evaluation of
CB expansion on MSCs is planned. The pre-clinical data support-
ing this approach as well as updates on the two clinical CB expan-
sion trials described above will be presented at the Los Angeles
meeting.
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IN VIVO STEM CELL FACTOR (R-METHUSCF) AND FILGRASTIM ADMIN-
ISTRATION AFTER UNRELATED UCB TRANSPLANTATION IN ADULTS
Laughlin, M.J. Department of Medicine and Pathology, Case Western
Reserve University, School of Medicine, Cleveland, OH
Allogeneic transplantation with HLA-mismatched unrelated
Umbilical Cord Blood (UCB) is marked by delayed hematologic
recovery when compared with conventional allogeneic graft
sources. UCB graft cell dose correlates with time to myeloid
recovery. Clinical studies have been conducted to improve UCB
graft cell dose including short-term ex vivo expansion, or infusion
of more than one UCB graft. This report summarizes transplant
outcomes for two adults with chronic myelogenous leukemia
(CML), who received myeloablative conditioning followed by in-
fusion of a non-expanded single UCB graft containing a low
mononuclear cell dose. These CML patients were enrolled in a
supportive care clinical transplant trial incorporating in vivo ad-
ministration of recombinant human stem cell factor (R-
MetHuSCF) and ﬁlgrastim administered concomitantly from day
of UCB infusion to time of donor-derived hematopoietic recovery.
Each patient engrafted promptly, with days to donor-derived ab-
solute neutrophil count (ANC) 500/L being 13 and 29 days
respectively. No adverse events attributable to R-MetHuSCF in-
jections were observed. ’In vivo UCB expansion’ with administra-
tion of concomitant R-MetHuSCF and ﬁlgrastim may facilitate
prompt donor hematologic engraftment in adult UCB transplant
recipients.
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AN ALGORITHM FOR SELECTION OF STEM CELL PRODUCTS FOR
TRANSPLANTATION
Barker, J.N. Memorial Sloan-Kettering Cancer Center, New York, NY
To date no prospective randomized studies of unrelated volun-
teer donor bone marrow transplantation (BMT) versus umbilical
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